Application of tomato exosome in preparation of medicine for relieving restenosis after vascular injury
Through the extraction and purification of tomato exosomes, biological agents were prepared to inhibit endovascular hyperplasia and smooth muscle cell proliferation, which solved the problem of restenosis after vascular interventional surgery, significantly reduced the occurrence of vascular restenosis, and provided a Safe and sustainable mass production treatment options.
Patent Information
- Application Number
- CN202411022222.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-12-06
AI Technical Summary
The problem of restenosis after vascular interventional surgery still lacks effective prevention and treatment methods, which is one of the important reasons for recurrence of cardiovascular events.
Tomato exosomes are used as a drug to prepare biological agents to alleviate restenosis after vascular injury by extracting, purifying and applying them to inhibit endovascular hyperplasia and proliferation of smooth muscle cells.
It significantly inhibits the proliferation and migration of vascular smooth muscle cells, reduces the occurrence of vascular restenosis, and provides a safe and sustainable large-scale production treatment plan.
Smart Images

Figure CN119074828A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological preparations, and in particular relates to the application of tomato exosomes in the preparation of a drug for alleviating restenosis after vascular injury. Background Art
[0002] Exosomes are small membrane vesicles (30-150nm) containing complex RNA and proteins. Nowadays, they specifically refer to disc-shaped vesicles with a diameter of 40-100nm. Exosomes are natural intercellular information carriers with small molecular structures and good biocompatibility, and have the potential to be developed into biological agents or drugs with therapeutic effects.
[0003] Plant exosomes have a diameter of about 40 to 150 nm, and are similar to animal exosomes in morphology and structure. They have a phospholipid bilayer structure and are nanoscale vesicles secreted by most cells. They are saucer-shaped or cup-shaped and consist of a large number of lipids, including microRNAs and proteins. At present, there is evidence that plant exosomes may be involved not only in plant cell-to-cell communication, but also in interspecies communication between plants and animals. Unlike animal exosomes, which are difficult to mass-produce, plant exosomes can be easily isolated and purified in large quantities. Natural exosomes isolated from edible plants such as grapefruit, broccoli and ginger overcome the limitations of synthetic nanoparticles by providing sustainable, large-scale, safe and economical treatment methods. For example, 350 to 450 mg of exosomes can be extracted from 100 g of various edible plants, indicating that these natural plant exosomes can be produced on a large scale economically and efficiently. In terms of safety, plants do not have any zoonotic or human pathogens, their lower immunological in vivo risks have been confirmed, and there is no risk of inducing elevated proinflammatory cytokines. At present, most of the research on exosomes is focused on animal exosomes, while there are relatively few studies on plant exosomes. Therefore, the study of plant exosomes is a newer research direction and research idea for diseases, and has a very broad research prospect.
[0004] Coronary heart disease is still one of the common causes of death in patients. Currently, the main treatment method is percutaneous transluminal coronary intervention (PCI). Statistics show that 6 months after coronary stent implantation, the incidence of restenosis after bare metal stent treatment is 25%, and the incidence of restenosis after drug-eluting stent treatment is 10%. At least 250,000 cases of restenosis after coronary artery disease treatment worldwide require re-intervention each year. Previous studies have shown that progressive restenosis after vascular injury is a healing process in which the body overreacts to external damage or foreign body stimulation, and is also a process of excessive intimal hyperplasia, involving a complex multi-step continuous process. Within a few hours after stent implantation, the expansion of the vascular wall by the stent will cause local vascular overstretching, and the stretched blood vessel will cause elastic retraction of the vascular wall due to damage to its endothelium. About 30% of patients after stent implantation will experience vascular restenosis through this process. Due to the lack of new targets for effective prevention and treatment, vascular restenosis is still one of the important reasons for the failure of target vessel intervention and even recurrence of adverse cardiovascular events. Lumen restenosis caused by vascular injury is related to the proliferation of vascular smooth muscular cells (VSMCs). The number of VSMCs increases 3-5 times in the first 2 weeks after injury, accounting for 90% of the total volume of the final neointima. After injury, platelets aggregate and release platelet-derived growth factors (PDGF) and other mitotic factors, penetrating the vascular wall to trigger the transformation of VSMCs from contractile to proliferative. Therefore, for patients with coronary heart disease who undergo PCI, how to avoid vascular restenosis and recurrent infarction has become a social focus issue related to the medium- and long-term prognosis of patients. Summary of the invention
[0005] In view of this, the present invention aims to propose the use of tomato exosomes in the preparation of drugs for alleviating restenosis after vascular injury, so as to solve the problem of vascular restenosis after interventional surgery injury.
[0006] To achieve the above object, the technical solution of the present invention is achieved as follows:
[0007] A first aspect of the present invention provides the use of tomato exosomes in the preparation of a drug for alleviating restenosis after vascular injury.
[0008] Furthermore, the restenosis after vascular injury is restenosis after vascular intervention surgery.
[0009] Furthermore, the drug for alleviating restenosis after vascular injury is used to inhibit vascular intimal hyperplasia.
[0010] Furthermore, the drug for alleviating restenosis after vascular injury is used to inhibit the proliferation and / or metastasis of vascular smooth muscle cells.
[0011] A second aspect of the present invention provides a method for preparing tomato exosomes, comprising the following steps:
[0012] S1: Squeeze the tomato juice and filter it to obtain the tomato liquid;
[0013] S2: centrifugally extract the tomato stock solution obtained in S1 to obtain tomato exosomes;
[0014] S3: Purify the tomato exosomes obtained in S2 using the sucrose cushion method.
[0015] Furthermore, the S1 specifically comprises the following steps: washing and peeling the tomatoes, sterilizing the tomatoes together with the slicing instrument, cutting the tomatoes into small pieces in a clean bench, adding PBS to the cut tomatoes and squeezing the juice to obtain a juice, and filtering the juice through sterile gauze to obtain a tomato stock solution.
[0016] Furthermore, the S2 specifically includes the following steps: taking out the tomato stock solution, pre-treating it, and moving it into a centrifuge tube, centrifuging it to obtain a first centrifuge; moving the supernatant of the first centrifuge into a new centrifuge tube, centrifuging it to obtain a second centrifuge; taking the supernatant of the second centrifuge, filtering it, and obtaining a filtrate; moving the filtrate into a new centrifuge tube, centrifuging it, and obtaining a third centrifuge; removing the supernatant of the third centrifuge, resuspending it with pre-cooled PBS, selecting an ultraspeed rotor, and ultracentrifuging it to obtain a fourth centrifuge; removing the supernatant of the fourth centrifuge, and resuspending it with pre-cooled PBS to obtain tomato exosomes.
[0017] Furthermore, the S3 specifically includes the following steps: adding pre-cooled PBS to the tomato exosomes to obtain a mixed solution; slowly adding the mixed solution to the sucrose cushion and centrifuging; taking out the 30% sucrose cushion located in the lower layer, diluting it with PBS, centrifuging it, removing the supernatant, and resuspending the precipitate with pre-cooled PBS to obtain purified tomato exosomes.
[0018] The third aspect of the present invention provides tomato exosomes obtained by the preparation method described in the second aspect of the present invention.
[0019] The fourth aspect of the present invention provides the use of the tomato exosomes described in the third aspect of the present invention in the preparation of a drug for alleviating restenosis after vascular injury.
[0020] Compared with the prior art, the present invention has the following advantages:
[0021] Exosome drugs have significant advantages over traditional drugs, which are reflected in the following aspects: exosomes are natural intercellular information carriers with small molecular structures and good biocompatibility; compared with ordinary drugs, exosomes have high bioavailability and good targeting. The tomato exosome-based biological preparation developed in this scheme to alleviate restenosis after vascular injury has ideal application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] The accompanying drawings constituting a part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the accompanying drawings:
[0023] Figure 1 This is a flow chart of the method for preparing tomato plant exosomes according to the present invention;
[0024] Figure 2 This is an electron microscope image of Tomato-exos of the present invention;
[0025] Figure 3 is the size distribution diagram of Tomato-exos;
[0026] Figure 4 This is the result of the control group of the in vitro cell scratch experiment;
[0027] Figure 5 This is the result diagram of the in vitro cell scratch test experimental group;
[0028] Figure 6 The results of the experimental and control groups of the in vitro cell Transwell experiment are shown in Figure 2.
[0029] Figure 7 This is a schematic diagram of HE staining of blood vessels in the experimental group and the control group 28 days after vascular injury surgery in mice. DETAILED DESCRIPTION
[0030] It should be noted that, in the absence of conflict, the embodiments of the present invention and the features in the embodiments may be combined with each other.
[0031] The present invention will be described in detail below with reference to the accompanying drawings and in conjunction with embodiments.
[0032] 1. Preparation of tomato exosomes
[0033] 1. Preparation of tomato stock solution: Wash and peel 1 catties of tomatoes, and sterilize them with alcohol together with the slicing equipment; cut the tomatoes into small pieces in a clean bench; add appropriate amount of PBS to the cut tomatoes and squeeze the juice to obtain 500 mL of juice, and filter it through sterile gauze to obtain the tomato stock solution.
[0034] 2. Extraction of tomato exosomes: The tomato stock solution was taken out for pretreatment and then moved to a centrifuge tube, and centrifuged at 1000×g, 4°C for 10 min to obtain the first centrifuge solution; the supernatant of the first centrifuge solution was transferred to a new centrifuge tube, and centrifuged at 3000×g, 4°C for 30 min to obtain the second centrifuge solution; the supernatant of the second centrifuge solution was taken and filtered to obtain the filtrate; the filtrate was transferred to a new centrifuge tube, and centrifuged at 10000×g, 4°C for 30 min to obtain the third centrifuge solution; the supernatant of the third centrifuge solution was removed, and the solution was resuspended with 10 mL of pre-cooled 1×PBS, and an ultraspeed rotor was selected, and the solution was ultracentrifuged at 150,000×g, 4°C for 60 min to obtain the fourth centrifuge solution; the supernatant of the fourth centrifuge solution was removed and resuspended with 200 μL of pre-cooled 1×PBS to obtain tomato exosomes.
[0035] 3. Purification of tomato exosomes: Use pre-cooled 1×PBS to make up the volume of tomato exosomes to 1 mL to obtain a mixed solution; slowly add 1 mL of the mixed solution to 250 μL of 30% sucrose cushion (prepared with heavy water), and centrifuge at 150,000×g for 60 min; take out 250 μL of the 30% sucrose cushion at the bottom layer, dilute it to 3 mL with PBS, and centrifuge it at 100,000×g for 60 min. Remove the supernatant and resuspend the precipitate with 200 μL of pre-cooled PBS to obtain purified tomato exosomes.
[0036] 2. Construction of cell model
[0037] Vascular smooth muscle cells (VSMC) were cultured in DMEM medium + 5% fetal bovine serum + 1% double antibody, and the medium was changed regularly. When the cells grew to 80% of the wall, the corresponding cell experiments were performed. 20ng / ml PDGF-bb was used to induce the proliferation, migration and phenotypic conversion of VSMC for 24 hours to simulate the pathological state of smooth muscle cells after vascular injury.
[0038] For the experimental group, 20ul / ml tomato exosomes were added at the same time as PDGF-bb, and the tomato exosomes were replaced with PBS in the control group. After 24 hours of treatment, the cell scratch test and Transwell migration test were observed to evaluate the migration trend of VMSCs.
[0039] 3. Construction of animal models
[0040] Construction of guidewire strain model: 6-8 week old C57B mice were anesthetized with 0.5% sodium pentobarbital, and the skin in the front of the left inguinal area was incised to expose and free the femoral artery and its branches, the superficial femoral artery and the deep femoral artery. A small hole was made in the deep femoral artery with small scissors. The tip of the curved micro-tweezers was inserted, followed by a metal guidewire with a diameter of 0.015 inches, which was slowly moved into the femoral artery. After staying for 1 minute, the metal guidewire was removed, blood flow was restored, and the deep femoral artery was ligated before and after the puncture point with a 9-0 nylon suture. For the control group, only the femoral artery was freed without straining the metal guidewire.
[0041] Drug treatment: After modeling, 100 mg / kg of tomato exosomes were injected through the tail vein for one week, and the mice were killed 28 days after injury.
[0042] Tissue section staining: 28 days after modeling, tibia samples were collected and fixed with 4% paraformaldehyde for 24 hours before HE staining to observe the restenosis of the femoral artery in mice.
[0043] IV. Experimental Results
[0044] like Figure 2 and Figure 3 As shown, the "tray-like" appearance of exosomes was discovered by transmission electron microscopy, and the particle size analysis verified that the particle size was consistent with that of exosomes, confirming the successful extraction of exosomes.
[0045] like Figure 4 As shown, the cell migration of the control group was recorded by cell scratch test. Figure 4 It can be seen that the cell migration area increased after 24 hours.
[0046] like Figure 5 As shown, the cell migration of the experimental group was recorded by cell scratch test. Figure 5 It can be seen that after 24 hours, the cell migration area was significantly reduced compared with the control group.
[0047] Figure 6 This is the result of the cell Transwell experiment. Figure 6 It can be seen that after 24 hours of exosome intervention, the experimental group can significantly inhibit cell migration compared with the control group.
[0048] Figure 7 For the wire strain experiment in C57 / B mice, Figure 7 It can be seen that the intimal hyperplasia in the experimental group was significantly reduced compared with the control group, which confirms that tomato exosomes have the effect of inhibiting restenosis after vascular injury.
[0049] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. Application of tomato exosomes in the preparation of drugs to alleviate restenosis after vascular injury.
2. The use according to claim 1, characterized in that: The restenosis after vascular injury is restenosis after vascular intervention surgery.
3. The use according to claim 1, characterized in that: The drug for alleviating restenosis after vascular injury is used for inhibiting vascular intimal hyperplasia.
4. The use according to claim 1, characterized in that: The drug for alleviating restenosis after vascular injury is used for inhibiting the proliferation and / or metastasis of vascular smooth muscle cells.
5. A method for preparing tomato exosomes, characterized in that: The following steps are involved: S1: Squeeze the tomato juice and filter it to obtain the tomato liquid; S2: centrifugally extract the tomato stock solution obtained in S1 to obtain tomato exosomes; S3: Purify the tomato exosomes obtained in S2 using the sucrose cushion method.
6. The method for preparing tomato exosomes according to claim 5, characterized in that: The S1 specifically comprises the following steps: washing and peeling the tomatoes, sterilizing the tomatoes together with the slicing instrument, cutting the tomatoes into small pieces in a clean bench, adding PBS to the cut tomatoes and squeezing the juice to obtain a juice, and filtering the juice through sterile gauze to obtain a tomato stock solution.
7. The method for preparing tomato exosomes according to claim 5, characterized in that: The S2 specifically includes the following steps: taking out the tomato stock solution, pre-treating it, and then moving it into a centrifuge tube, centrifuging it to obtain a first centrifuge liquid; moving the supernatant of the first centrifuge liquid into a new centrifuge tube, centrifuging it to obtain a second centrifuge liquid; taking the supernatant of the second centrifuge liquid, filtering it to obtain a filtrate; moving the filtrate into a new centrifuge tube, centrifuging it to obtain a third centrifuge liquid; removing the supernatant of the third centrifuge liquid, resuspending it with pre-cooled PBS, selecting an ultraspeed rotor, ultracentrifuging it to obtain a fourth centrifuge liquid; removing the supernatant of the fourth centrifuge liquid, resuspending it with pre-cooled PBS, and obtaining tomato exosomes.
8. The method for preparing tomato exosomes according to claim 5, characterized in that: The S3 specifically includes the following steps: adding pre-cooled PBS to the tomato exosomes to obtain a mixed solution; slowly adding the mixed solution to the sucrose cushion and centrifuging; taking out the 30% sucrose cushion located in the lower layer, diluting it with PBS, centrifuging it, removing the supernatant, and resuspending the precipitate with pre-cooled PBS to obtain purified tomato exosomes.
9. Tomato exosomes obtained according to the preparation method according to any one of claims 5 to 8.
Citation Information
Patent Citations
Hemostatic hydrogel as well as preparation method and application thereof
CN115671371A
Plant-derived exosome as well as preparation method and application thereof
CN118308283A
Therapeutic uses of tomato extracts
US20090123584A1
AU2013204025A1
